These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37547978)

  • 1. Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy.
    Hanaya R; Kubota Y; Mizobuchi M; Iida K; Ono T; Motooka H; Nakano N; Fujimoto A; Iwasaki M; Fukuda M; Kondo A; Uruno K; Yamamuro S; Yamaguchi K; Onishi K; Ngo LY; Inoue Y
    Epilepsia Open; 2023 Dec; 8(4):1369-1382. PubMed ID: 37547978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis.
    Omatsu H; Watanabe T; Kira R; Ishiba K; Patten A; Takase T; Ngo LY
    Seizure; 2023 Aug; 110():109-116. PubMed ID: 37336055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
    Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
    Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study.
    Hussein Z; Majid O; Boyd P; Aluri J; Ngo LY; Reyderman L
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):878-888. PubMed ID: 35596529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
    Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY
    Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
    Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
    Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
    Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.
    Yamamoto T; Gil-Nagel A; Wheless JW; Kim JH; Wechsler RT
    Epilepsy Behav; 2022 Nov; 136():108885. PubMed ID: 36150304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of perampanel monotherapy in Chinese patients with focal-onset seizures: A single-center, prospective, real-world observational study.
    Ma H; Zhu H; Chen F; Yang Y; Qu X; Xu H; Yang L; Zhang R
    Epilepsia Open; 2023 Dec; 8(4):1474-1483. PubMed ID: 37661647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
    Piña-Garza JE; Villanueva V; Rosenfeld W; Yoshinaga H; Patten A; Malhotra M
    Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of perampanel monotherapy after adjunctive therapy through retention rate in subjects with focal-onset seizures with or without focal to bilateral tonic-clonic seizures: A multicenter retrospective study in Korea.
    Lim SC; Lee WG; Kim DW; Kim KK; Shon YM; Park J; Lee Y; Seo DW
    Epilepsy Behav; 2023 Aug; 145():109291. PubMed ID: 37336136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
    Rektor I; Krauss GL; Inoue Y; Kaneko S; Williams B; Patten A; Malhotra M; Laurenza A; Wechsler RT
    Epilepsia; 2020 Jul; 61(7):1491-1502. PubMed ID: 32645213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects.
    Jing S; Shiba S; Morita M; Yasuda S; Lin Y
    Clin Drug Investig; 2023 Mar; 43(3):155-165. PubMed ID: 36746851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term open-label perampanel: Generalized tonic-clonic seizures in idiopathic generalized epilepsy.
    French JA; Wechsler RT; Trinka E; Brandt C; O'Brien TJ; Patten A; Salah A; Malhotra M
    Epilepsia Open; 2022 Sep; 7(3):393-405. PubMed ID: 35445567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
    Resnick T; Patten A; Ngo LY; Malhotra M
    Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy.
    Inoue Y; Kaneko S; Hsieh PF; Meshram C; Lee SA; Aziz ZA; Nabangchang C; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ; Patten A; Williams B; Malhotra M
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.